Results 171 to 180 of about 1,925 (192)

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

Journal of Infectious Diseases, 2022
Matthieu Beuvelet, Aditya Sardesai, Robert Musci   +2 more
exaly  

Nirsevimab for Prevention of RSV Hospitalizations in Infants

New England Journal of Medicine
Saul N, Faust, Simon B, Drysdale, Natalya C, Vassilouthis   +2 more
openaire   +3 more sources

Nirsevimab for RSV Prophylaxis in Healthy Infants

AAP Grand Rounds, 2022
openaire   +1 more source

Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts

Pediatrics
Claire, Abraham, Jon, Hatoun, Emily Trudell, Correa, Naveed, Rabbani, Louis, Vernacchio   +4 more
openaire   +2 more sources

Nirsevimab

Reactions Weekly
openaire   +1 more source

Nirsevimab—a breakthrough in respiratory syncytial virus bronchiolitis

The Lancet Child & Adolescent Health
Assad, Zein, Papenburg, Jesse, Ouldali, Naïm   +2 more
openaire   +3 more sources

Nirsevimab para la prevención de la enfermedad por virus respiratorio sincitial en niños. Posicionamiento de la Sociedad Española de Infectología Pediátrica

Anales De Pediatría, 2023
exaly  

Factors Associated With Nirsevimab Uptake in Healthy Newborns

Hospital Pediatrics
Elena, Aragona, Veronika, Shabanova, Jaspreet, Loyal   +2 more
openaire   +2 more sources

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France

EClinicalMedicine
François Dubos
exaly  

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Journal of Infection
Ushma Wadia, Catherine Pienaar
exaly